Respiratorius (RESP) Q1 2026 earnings summary

Executive summary

• Focused business development efforts in Q1 2026 led to positive market feedback, especially for the VAL001 candidate, with several pharmaceutical companies evaluating the project internally.

• Participation at BIO Europe Spring 2026 resulted in valuable meetings and ongoing evaluations by potential partners.

• No major external news communicated during the period, but patent protection for VAL001 was strengthened with new validations in SE, UK, and FR.

• Current financing is assessed as sufficient to operate through February 2027.

Financial highlights

• Net sales for Q1 2026 were 0 KSEK, unchanged from Q1 2025.

• Result after financial items improved to -1,732 KSEK from -2,006 KSEK year-over-year.

• Earnings per share were -0.22 SEK, compared to -0.39 SEK in Q1 2025.

• Cash and bank balances at period end were 4,656 KSEK, down from 5,151 KSEK a year earlier.

Outlook and guidance

• Management expects current funding to be adequate until February 2027, supporting ongoing business development and patent activities.

• The company is optimistic about securing a partnership agreement for VAL001.